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Background: Elimination of mother-to-child transmis-
sion (MTCT) of HIV by 2020 is a goal of the World Health 
Organization (WHO) action plan for the European 
Region. However, data to monitor progress towards 
MTCT elimination are not readily available in Germany.
Aim: We aimed to estimate the number of pregnant 
women with HIV and MTCT rates in Germany. Methods: 
We triangulated retrospectively obtained data from: (i) 
healthcare reimbursement for HIV screening tests, (ii) 
a statutory health insurance subsample of prevalent 
and incident HIV diagnoses among pregnant women, 
(iii) a mathematical model of the German HIV epi-
demic with number, region of origin and risk factors 
for women of childbearing age, and (iv) the statutory 
anonymous HIV registry on children infected through 
HIV MTCT. Results: The number of women aged 15–49 
years with HIV increased from ca 6,000 in 1993 to 
ca 11,000 in 2016. Risk of injecting drug use (IDU) 
declined from 65% in 1993 to 16% in 2016. The annual 
proportion of women living with HIV giving live birth 
increased from a mean of 1.9% during 1993 to 1998 
to 4.9% in 2011 to 2015. HIV screening rates during 
pregnancy increased from ca 50% in 2001 to ca 90% in 
2016. The HIV MTCT rate dropped from 6.8% in 2001 to 
1.1% in 2016. Conclusions: The population of women 
living with HIV in Germany shifted from predominantly 
IDU-associated infections to predominantly sexually 
acquired infections, while fertility rates more than dou-
bled. MTCT rates dropped, mainly because of improved 
detection and management of HIV in pregnancy.
Introduction
In 2016, the World Health Organization Regional Office 
for Europe (WHO/Europe) published an ‘Action plan for 
the health sector response to HIV in the WHO European 
Region’ [1]. It announced the WHO target to eliminate 
mother-to-child transmission (MTCT) of HIV in the 
European region by 2020 .
The elimination targets specific to the prevention of 
MTCT were to: (i) reduce MTCT to < 2% in non-breast-
feeding populations and (ii) reduce the rate of HIV and 
congenital syphilis in infants. This should be achieved 
by setting national targets, expanding coverage with 
antenatal care and testing (including in key popula-
tions), providing lifelong antiretroviral treatment (ART) 
for women during pregnancy and after delivery, and 
ensuring early diagnosis of infants and immediate 
treatment for all infants diagnosed with HIV.
Two indicators were proposed to measure progress 
towards these targets: (i) HIV MTCT rate, i.e. the per-
centage of infants born to HIV-positive women in the 
past 12 months who become infected with HIV and (ii) 
HIV MTCT case rate, i.e. the number of new congenital 
HIV MTCT cases per 100,000 live births.
Effective measures to prevent or reduce MTCT have 
been established: (i) Caesarean section to reduce 
exposure to maternal blood during delivery [2], (ii) 
antiretroviral treatment during pregnancy with the goal 
to have an undetectable viral load at delivery [3,4]; (iii) 
postpartum post-exposure prophylaxis (PEP) for the 
newborn with antiretroviral drugs [5], and (iv) formula 
feeding instead of breastfeeding to avoid HIV transmis-
sion via breastmilk [6]. Meanwhile it has been shown 
that Caesarean section has no additional benefit if 
maternal viral load is undetectable at delivery, and it 
is debated whether postpartum PEP for the newborn 
is still required if maternal viral load was undetectable 
during the last weeks of pregnancy [7]. The need for 
formula feeding is also under discussion if the mother 
is effectively treated for HIV [8].
In Germany, prenatal care is guided by maternity care 
guidelines that include recommendations on test-
ing and other preventive activities for prenatal care. 
Pregnant women receive a ‘maternity passport’ in 
which the attending physician documents tests and 
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findings relevant for prenatal care.  Table 1  shows the 
history of inclusion of HIV screening into these prenatal 
care guidelines. Recommendations on HIV testing and 
on how to manage HIV infection during pregnancy and 
delivery were first introduced in Germany during the 
1990s in specific clinical HIV pregnancy guidelines. The 
first general maternity care guidelines that included 
recommendations on HIV were only published in 2003 
[9].
The strategic approach for preventing HIV MTCT in 
Germany since the mid-1990s has included univer-
sal voluntary HIV testing during pregnancy, offering 
treatment to all pregnant women found to be infected, 
including postnatal infant prophylaxis if necessary. 
Medical guidelines on HIV treatment and MTCT prophy-
laxis during pregnancy, delivery and in the immediate 
postnatal period have been updated regularly [10].
Unfortunately, in Germany as in many other countries, it 
is difficult to monitor progress in the prevention of HIV 
MTCT because of a lack of appropriate data sources for 
some key data. In Germany, there are no readily avail-
able national-level data on the number of: (i) pregnant 
women and women delivering a baby who have been 
tested for HIV, (ii) pregnant women first diagnosed 
with HIV during their current pregnancy, (iii) pregnant 
women first diagnosed with HIV during their current 
pregnancy and deciding to continue their pregnancy 
and deliver the baby, and (iv) women already known to 
have HIV who get pregnant and deliver a baby.
Surveillance in Germany provides data on newly diag-
nosed HIV infections among children and newborns and 
data on newly diagnosed HIV infections among women. 
However, surveillance data neither provide information 
on the pregnancy status of women diagnosed with HIV 
nor complete information on the number of newborns 
potentially exposed to HIV during pregnancy. Thus, 
while calculating the second of the two WHO indicators 
(HIV MTCT case rate) has been possible, the denomina-
tor for the first indicator (MTCT rate) has been missing.
Healthcare reimbursement data are one data source 
that might help fill this gap. Health insurance, either 
through statutory health insurance (SHI) or private 
health insurance, is obligatory in Germany. SHIs cover 
ca 85–90% of pregnancies in Germany while private 
health insurances cover ca 10%. The vast majority of 
the population is therefore covered by health insur-
ance. We aimed to use healthcare reimbursement 
data from a large sample of women who received 
pregnancy-related healthcare to estimate: (i) the pro-
portion of all pregnancies and pregnancies resulting in 
child birth screened for HIV, (ii) the number of newly 
diagnosed HIV infections among pregnant women, and 
(iii) the number of women with an already-diagnosed 
HIV infection becoming pregnant across a period of 5 
years, from 2011 through 2015.
 
Methods
In our retrospective observational study, we used data 
from national population statistics, healthcare reim-
bursement data from a large sample of women who 
received pregnancy-related healthcare, transmission 
group-specific HIV prevalence estimates for women 
of child-bearing age (i.e. 15–49 years) from the early 
1990s to the present from the German HIV epidemic 
model, which is a modified back-calculation model, 
and HIV reporting data of perinatally infected children 
from the anonymous HIV registry at the Robert Koch 
Institute.
Table 1
Evolution of prenatal care guidelines with respect to HIVa, Germany, 1985–2015
Guideline version HIV-related recommendations
1985 Prenatal care 
guidelines
HIV not mentioned. 
 
Generic recommendations regarding serological testing for infections and appropriate treatment and care for 
infections.
1990s HIV and pregnancy 
guidelines
Specialist guidelines for HIV and pregnancy: recommendations on HIV testing and on how to manage HIV 
infection during pregnancy and delivery (regularly updated since then). While these guidelines are usually 
comprehensive and up to date, they are not well known among general gynaecologists.
2003 Prenatal care 
guidelines
First version of general prenatal care guidelines including HIV screening recommendations: ‘voluntary serological 
testing for HIV antibodies after medical counselling about HIV and MTCT transmission risks, if appropriate’. 
 
HIV screening was recommended at the first antenatal screening visit within the first 12 weeks of pregnancy. 
 
There was no space in the ‘maternity passport‘ to document HIV testing (in contrast to all other recommended 
screening tests).
2007 Prenatal care 
guidelines Inclusion of an explicit statement that an HIV screening test should be recommended to every pregnant woman.
2015 Prenatal care 
guidelines
Introduction of a tick box in the ‘maternity passport‘ to indicate whether an HIV screening test had been 
performed.
a The German prenatal care guidelines are the essential resource for the delivery of prenatal care in Germany.
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Data sources and calculations
Total number of pregnancies and pregnancy outcomes 
in Germany
The total number of pregnancies and pregnancy out-
comes for 2001 through 2016 were obtained from offi-
cial German population statistics [11]. Number of births 
was transformed to number of pregnancies by adjust-
ing for twin and triplet births.
Number of pregnant women with HIV
SHI reimbursement data from a large sample of women 
who received pregnancy-related healthcare with HIV-
specific reimbursement codes were used to estimate 
the number of already known and newly discovered HIV 
infections among pregnant women for 2011 to 2015.
For 1993 to 1998, a research project in the federal 
states of Berlin and Lower Saxony screened all residual 
blood samples from phenylketonuria (PKU) screening 
for HIV antibodies [12]. From these data, HIV prevalence 
among women giving birth was determined for these 
years and federal states. However, whether the women 
were aware of having HIV is not known for these data. 
No information on the number of premature pregnancy 
terminations among women living with HIV in these 
two federal states during this period was available.
Number of HIV screening tests during pregnancies 
reimbursed by statutory health insurances and by 
private health insurance
The total number of HIV screening tests during pregnan-
cies reimbursed by SHI in Germany was queried from 
Kassenärztliche Bundesvereinigung (KBV), a central 
agency that collects all SHI reimbursement claims, for 
2001 through 2016. However, the actual timing of the 
HIV screening test is not reported and may be delayed 
by late presentation of pregnant women for antenatal 
care.
The denominator for the HIV screening tests is unclear 
for these data and is somewhere between the total 
number of pregnancies among SHI-covered women and 
the total number of pregnancies resulting in live births, 
but probably closer to the number of pregnancies. So to 
estimate the denominator, the number of pregnancies 
Table 2
EBM codes and ICD-10 diagnoses used for retrieval of data on pregnancies and HIV from the Health Risk Institute, 
Germany, 2011–2015
Feature Catalogue EBM code/ICD-10 diagnosis Designation
Screening
EBM 01770 Care for a pregnant woman
EBM 32007 Check-ups in accordance with the German maternity guidelines
Birth
ICD-10 O80 Spontaneous delivery of a singleton
ICD-10 O81 Birth of a singleton by forceps or vacuum extraction
ICD-10 O82 Birth of a singleton by Caesarean section
ICD-10 Z37.0/2/3/5/6/9 Live-born singleton/twin/multiple
ICD-10 Z38a Live births by birthplace
HIV test
EBM 01811 HIV immunoassay
EBM 32575 HIV-1 or HIV-1/2 antibody immunoassay
EBM 32576 HIV-2 antibody immunoassay
EBM 32783 Detection of HIV
HIV confirmatory test
EBM 32824 HIV RNA
EBM 32660 HIV-1, HIV-2 antibody Western blot
Exclusion criteria
HIV-specific services
EBM 30920 Flat rate for the treatment of HIV-infected persons
EBM 30922 Supplement Ib for the treatment of HIV-infected persons
EBM 30924 Supplement IIb for the treatment of HIV-infected persons
Pre-existing HIV 
diagnosis
ICD-10 O98.7 HIV disease complicating pregnancy, childbirth and puerperium
ICD-10 R75 Laboratory evidence of HIV
ICD-10 B20-B24 Infectious and parasitic diseases/malignant neoplasms/other diseases because of HIV disease
ICD-10 Z21 Asymptomatic HIV infection
ICD-10 U60 Clinical categories of HIV disease
ICD-10 U61 Number of CD4+ T cells in HIV disease
EBM: Einheitlicher Bewertungsmaßstab (statutory insurance fees); ICD: international classification of diseases.
a The ICD-10 code Z38 should generally be used to encode childbirth in the newborn. Since newborns often do not have their own insurance 
number at the beginning of life, billing is carried out via the maternal insurance number. To be certain to capture all births, this ICD-10 code 
was also included in the case definition.
b The supplements are bonus payments to cover the increased demand of time and other resources for the care of HIV-infected patients.
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covered by SHI, two methods were used: (i) subtrac-
tion of the estimated number of newborns covered by 
private health insurance (see below) from the total 
number of live births as obtained from official popula-
tion statistics and (ii) the number of syphilis screening 
tests reimbursed by SHI as reference, assuming that 
syphilis screening in pregnancy has reached an almost 
universal coverage.
As there are no data on the number of pregnancies cov-
ered by private health insurance, the number of new-
borns covered by private health insurance was used as 
a proxy. The latest available estimate was for the years 
2000 through 2010 [13]. For the estimate from 2001 to 
2016, it was assumed that the proportion of women 
giving birth and covered by private health insurance 
remained unchanged from the 2010 levels. There are 
also no available data on HIV screening during preg-
nancy for privately ensured women. Since private 
health insurance reimbursements are generally higher 
than SHI reimbursements, there is a financial incentive 
for healthcare providers to offer at least the same ser-
vices for privately ensured clients. For our analysis, it 
was assumed that the HIV screening rate among pri-
vately insured women is equivalent to that among SHI-
covered women.
Some pregnant women with assumedly increased risk 
of HIV MTCT, such as asylum seekers, undocumented 
women and women from European Union (EU) coun-
tries without valid health insurance in Germany are not 
included in either of these two datasets.
Pregnancies resulting in live births with HIV screening 
tests performed
About 87% of German inhabitants (70.3 million) are 
insured at one of 123 German SHIs. To estimate the 
proportion of pregnancies resulting in live births in 
which an HIV screening test was ordered, health insur-
ance reimbursement data for a subsample available in 
the database of the German Health Risk Institute (HRI) 
were analysed. As at 31 December 2013, 82 German 
SHIs contribute longitudinal data from ca 6 million 
Germans. The HRI database provided data on 6.9% of 
the pregnancies that resulted in live births in Germany 
in the period 2011 to 2015.
Data are anonymised with respect to individual insur-
ant, healthcare provider (e.g. physicians, practices, 
hospitals and pharmacies) and the respective SHI. In 
addition to anonymisation, access to the data is strictly 
controlled. It is prohibited to transmit patient-level 
data, and all data analyses had to be performed by HRI 
employees or trained associated researchers.
The estimated delay of data being available in the data-
base is ca 3 to 9 months, e.g. healthcare data until 31 
December 2015 can be expected to be available in the 
database at September of 2016 at the latest.
The following was extracted from the HRI database: (i) 
demographic information, i.e. sex, age, region of resi-
dence, of all insured individuals alive on 31 December 
2013 and (ii) outpatient services and diagnoses as well 
as hospital case information including admission and 
discharge dates, major and minor diagnoses, and diag-
nostic and therapeutic services performed between 
2010 and 2015. The ICD codes used to extract informa-
tion on pregnancies and HIV from the HRI database are 
listed in Table 2.
A statistical approach was used to extrapolate the data 
generated from the HRI database subsample to the 
general population or to all pregnancies by weighting 
the data: results were standardised for age. Weights 
were calculated for the insured population of the HRI 
database by adjusting to the age and sex distribution 
of the total population in Germany from 2011 to 2015.
HIV-diagnosed and HIV-infected women
Based on a modified back-calculation model, the 
Robert Koch Institute (RKI) has been estimating the 
course and status of the HIV epidemic in Germany 
since 2010. For this analysis, data reported as at the 
end of 2016 was used to estimate the prevalence of HIV 
diagnoses and infections in women aged 15 to 49 years 
by federal state, transmission risk and region of origin 
[14].
Women living with HIV and giving live birth
The proportion of women living with HIV and giving 
live birth (numerator: number of women living with HIV 
giving live birth; denominator: estimated number of 
women in the age group 15 to 49 years of age living 
with HIV in Germany) was estimated. For 1993 to 1998, 
this was based on data from the anonymous unlinked 
HIV testing of left-over samples from PKU screening of 
newborns and the prevalence rates of women living 
with HIV from the RKI HIV estimate for the two federal 
Figure 1
Number of pregnancies resulting in live birth and 
estimated proportion screened for HIV, Germany, 2001–
2016 (n = 11,107,882)
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states of Berlin and Lower Saxony [12]. For 2011 to 
2015, the estimated number of HIV pregnancies from 
the health insurance reimbursement data and the esti-
mated total number of women living with HIV in the age 
group 15 to 49 years available from the RKI epidemic 
model were used. For both periods, a mean value was 
determined. The evolution of the calculated propor-
tion in the years between (1999–2010) and after (2016) 
those two periods was imputed considering the com-
position of women of childbearing potential by region 
of origin and risk of infection.
HIV diagnoses among children born in Germany
Data on HIV diagnoses among children born in 
Germany between 2001 and 2016 were taken from the 
anonymous, statutory HIV infection registry at the RKI. 
Since 2004, infections reported from children younger 
than 15 years of age have been verified by contacting 
the reporting physician regarding age, place of birth, 
and any information available on possible reasons for 
late diagnosis or failure of established procedures to 
prevent MTCT of HIV.
HIV mother-to-child transmission rates
HIV MTCT rates for 2001 to 2016 were estimated by 
dividing the number of HIV infections diagnosed among 
children born in a given year in Germany and the esti-
mated number of women living with HIV and giving live 
birth in that year.
Availability of additional data and material
Additional data tables including birth statistics, 
healthcare reimbursement data, data on a HIV preg-
nancy cohort from the SHI- subsample, estimates on 
the number of women living with HIV in Germany from 
mathematical modelling, measured and imputed fer-
tility rates for women living with HIV in Germany, and 
data on HIV infections in children born in Germany and 
reported to the HIV registry at the RKI are available as 
Supplementary material.
Ethical statement
PKU samples tested in the study from 1993 to 1998 
were anonymised and unlinked before HIV testing. 
Other data used are either healthcare reimbursement 
data or estimates based on surveillance data. Hence, 
no ethics approval or individual consent was required.
Results
According to German national population statistics, the 
number of pregnancies in Germany from 2001 to 2016 
fluctuated between 768,464 in 2011 (minimum) and 
887,115 in 2016 (maximum). The number of pregnancies 
resulting in live birth ranged between 657,210 in 2011 
and 785,480 in 2016.
Proportion of pregnancies with HIV screening, 
2001–2016
The estimated proportions of women giving live 
birth who were screened for HIV during 2001 to 2016 
is shown in  Figure 1. The number of HIV screening 
tests reimbursed by SHI increased from 398,784 in 
2001 to 711,826 in 2016. Assuming an equal screen-
ing rate for women covered by private health insur-
ance, the proportion of women giving live birth and 
screened for HIV during pregnancy increased from 52% 
(376,660/729,171) in 2001 to 92% (720,313/785,480) 
in 2016.
The proportion of pregnant women giving live birth that 
had been screened for HIV in our SHI sample increased 
slowly but consistently from 82.3% in 2011 to 87.0% 
in 2015 (Supplementary Table S1). Extrapolated to 
all live births, this would still leave between 114,000 
and 89,000 pregnant women giving birth unscreened. 
Testing rates differed by age group, with lower rates in 
older age groups (Figure 2).
Pregnant women with HIV in the statutory 
health insurance subsample, 2011–2015
The proportion of pregnant women giving live birth with 
a reactive HIV screening test result requiring confirma-
tory testing ranged between 0.09% (n = 492) and 0.14% 
(n = 725), with no clear time trend (Supplementary 
Table S1). During the 5-year period, the mean propor-
tion of confirmatory tests that resulted in HIV diagnosis 
in health insurance data was 19% (range: 11–26%). This 
Figure 2
HIV testing rates in women giving live birth, by age 
group, statutory health insurance subsample, Germany, 
2011–2015 (n = 203,160)
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corresponds to HIV diagnosis rates between 0.02% and 
0.07% of the women tested (Supplementary Table S1).
The mean estimated yearly number of new HIV diag-
noses among pregnant women in Germany between 
2011 and 2015 was 130, ranging between 68 and 201. 
In the same period, the estimated mean number of 
women with already known HIV diagnosis who became 
pregnant and gave live birth was 354 per year, with a 
range between 276 and 434. A mean number of 484 
pregnancies among women living or newly diagnosed 
with HIV was observed per year in the period 2011 to 
2015. The majority, 73% (1,771/2,420), were pregnan-
cies in women already diagnosed with HIV while 27% 
(648/2,420) were detected by pregnancy screening 
(Supplementary Table S1).
Number and composition of HIV-diagnosed 
and HIV-infected women, 1993–2016
The estimated number of women in the age group 15 to 
49 years living with HIV in Germany increased from ca 
6,000 in 1993 to almost 11,000 in 2016 (Supplementary 
Table S2). The composition of these women changed 
considerably over time; the proportion of women who 
became infected while injecting drugs intravenously 
decreased from 65% (n = 3,880) in 1993 to 16% 
(n = 1,730) in 2016 while the proportion of women who 
acquired HIV sexually within Germany, Africa, Asia or 
Figure 3
Composition of the 15–49 year age group of women living with HIV, by transmission risk factor and region of origin, and 
estimated proportion becoming pregnant per year, Germany, 1993–2016
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other European countries increased accordingly (Figure 
3, Supplementary Table S2). 
The mean proportion of women living with HIV who 
gave live birth in the period 1993 to 1998 in the federal 
states of Berlin and Lower Saxony was 1.9% (range: 
1.6–2.7%) based on the estimated number of women 
living with HIV in the two states and the number of HIV-
positive test results in the left-over samples from the 
PKU newborn screening study in these years (Figure 3). 
The estimated proportion of women living with HIV giv-
ing live birth in the period 2011 to 2015 was close to 5% 
(range: 3.7–6.0%) based on health insurance data and 
the prevalence in the epidemic model. It can be con-
cluded that the proportion of women giving live birth 
among women living with HIV in Germany increased 
considerably between 2000 and 2010, and the evo-
lution of this proportion was estimated based on an 
assumed linkage with the proportion of women who 
acquired HIV sexually. During the time period 1999 to 
2015, the proportion of women giving live birth among 
all women aged 15–45 years ranged between 4% and 
5%.
In an estimated 13.1% of the pregnancies with a reac-
tive HIV screening test of the mother in the 2011 to 2015 
health insurance subsample, the pregnancy was pre-
maturely terminated.
HIV mother-to-child transmission rates, 
2001–2016
The number of children born in Germany between 1999 
and 2016 who had acquired HIV perinatally and were 
diagnosed and reported by 31 December 2018 was 164. 
The HIV case rates (number of HIV MTCT per 100,000 
live births) for 2001 to 2016 are shown in Table 3.
Based on the estimated number of women living with 
HIV in Germany, becoming pregnant and giving live 
birth (estimated proportion of women living with HIV 
and giving live birth × number of women living with HIV 
in Germany and aged 15–49 years) the MTCT rates for 
2001 through 2016 were calculated. The rates dropped 
from 6.8% in 2001 to values fluctuating between 0.4% 
and 1.1% in 2013 to 2016 (Figure 4,  Supplementary 
Table S2). In the same period, the HIV screening rates 
in pregnancy had increased from ca 50% to ca 90% 
(Figure 4).
In the period 2011 to 2015, 24 children were born with 
HIV in Germany. In 12 cases, the mother had been 
newly diagnosed with HIV during pregnancy, in five 
cases, before she became pregnant. This represents 
an overall estimated HIV transmission rate of 1.0%, 
with 0.3% among women already diagnosed with HIV, 
and 1.9% among women diagnosed during pregnancy 
(Supplementary Table S1). For the remaining seven 
cases, the HIV status of the mother was unknown at 
the time of birth.
In recent years, only five of 24 HIV MTCT cases could 
be attributed to lack of HIV screening, while 19 cases 
were because of various other reasons (Supplementary 
Table S1). The single most important of these other 
reasons was difficulty to access prenatal care in time 
because of migration-related access barriers.
Discussion
The coverage of pregnancies with HIV screening tests 
has improved considerably over the study period 2001 
to 2016, but a sizeable proportion of ca 10% of deliver-
ies in 2016 still appeared to occur without evidence of 
HIV testing of the mother. Assuming that failure to test 
for HIV in these 10% is at random, the number of missed 
maternal HIV infections would have been around 37 in 
2011 and 2012, declining to 10–15 in the years 2013 to 
2016. This could have resulted in ca 3–5 MCTC annually 
in the years since 2013. According to the experience of 
the years since 2011, the number of infections in chil-
dren because of lack of screening of the mothers was 
lower: the maximum number observed per year was 
two, although it cannot be excluded that some infec-
tions have not yet been diagnosed. It appears more 
likely that in most cases when HIV tests are not offered 
or not accepted, healthcare providers and/or pregnant 
women rightly assume that their odds of having HIV are 
very low. However, at least one to two HIV MTCT per 
year could be avoided if the remaining 10% of pregnan-
cies would be covered with HIV screening.
The discrepancies between the different methods to 
estimate the coverage of pregnancies with HIV screen-
ing are mainly because of uncertainties about the 
exact proportion of pregnancies that were covered by 
SHI in the period 2011 to 2016. It was assumed that the 
Table 3
HIV case rate, HIV mother-to-child transmission per 
100,000 live births, Germany, 2001–2016
Year Number of live births HIV MTCT cases
HIV MTCT per 
100,000 live births
2001 734,475 15 2.042
2002 719,250 14 1.946
2003 706,721 12 1.698
2004 705,622 16 2.268
2005 685,795 13 1.896
2006 672,724 16 2.378
2007 684,862 6 1.314
2008 682,514 5 1.172
2009 665,142 8 1.353
2010 677,947 6 1.033
2011 662,685 5 0.905
2012 673,544 8 1.188
2013 682,069 2 0.293
2014 714,966 5 0.699
2015 737,575 3 0.407
2016 792,495 6 0.757
MTCT: mother-to-child transmission.
8 www.eurosurveillance.org
proportion remained constant at the 2010 level, but 
since 2011, Germany has experienced increased immi-
gration and it is likely that recent immigrants would be 
disproportionally covered by SHI or other mechanisms, 
e.g. publicly funded healthcare for asylum seekers.
The number of confirmatory tests for HIV among preg-
nant women was approximately five- to six fold higher 
than the number of new HIV diagnoses. There may 
be different explanations for this discrepancy: repeat 
confirmatory testing, e.g. because of referral to an HIV 
specialist after primary diagnosis or, probably more 
relevant, the low positive predictive value of reactive 
HIV screening tests because of the low prevalence in 
the population screened.
Approximately one in three pregnancies of women liv-
ing with HIV is newly diagnosed during that pregnancy. 
However, the proportion of women being diagnosed 
with HIV during pregnancy and not carrying on their 
pregnancy in the period 2011 to 2015 did not differ from 
the proportion of women not diagnosed with HIV (13% 
vs 12–15%).
Our data suggest a more than twofold increase of fer-
tility rates among the population of women living with 
HIV in Germany from the end of the 1990s until 2015. 
In the author’s opinion, this is probably because of 
at least two factors. One is the changing composition 
of the female population living with HIV. In the 1980s 
and 1990s women acquired HIV predominantly by IDU, 
whereas now increasing proportions of women acquire 
HIV sexually. The second factor could be that women 
who inject drugs more often terminate pregnancies pre-
maturely [15,16] and migration to Germany from regions 
with higher mean fertility rates than in Germany [17,18] 
and high HIV prevalence in the general population has 
increased [19,20]. Similar changes in the female popu-
lation living with HIV have been reported from other 
western European countries [21]. Among women living 
with HIV, the mean proportion giving live birth per year 
between 2011 and 2015 was 4.9%, which is very close 
to the proportion calculated for women from the gen-
eral population in Germany for this period [22]. Since 
it was not possible to control the German fertility rates 
for region of origin of the mother, it remains unclear 
whether and to what extent fertility rates of women 
living with HIV in Germany are lower than their unin-
fected peers. Comparative analysis of fertility rates of 
women living with HIV and other women from countries 
in sub-Saharan Africa, the Caribbean, and South-East 
Asia based on data collected in Demographic and 
Health Surveys (DHS) concluded that fertility rates of 
women living with HIV in these countries were gener-
ally lower than their uninfected peers [23]. However, 
most of these DHS were conducted more than a decade 
ago, and the reasons for lower fertility with HIV diag-
nosis include behavioural changes after HIV diagnosis. 
Improved quality of life, increased life expectancy and 
improved prospects to avoid HIV MTCT with improved 
HIV treatment, may impact on the desire of women liv-
ing with HIV to have children [4,24].
Although the female child-bearing population living 
with HIV has almost doubled and the proportion of 
women giving live birth in this population has almost 
tripled, the number of HIV-infected children, the 
case rate of HIV MTCT and the rate of HIV MTCT have 
decreased to levels below the targets foreseen by 
the WHO for the European Region. This is most likely 
because of the increasing HIV screening rates dur-
ing pregnancy and the highly effective medical inter-
ventions such as antiretroviral treatment of pregnant 
women to prevent HIV MTCT.
Limitations
The number of children who acquired HIV perinatally in 
Germany may be underestimated, particularly for more 
recent years, because some infections are still undi-
agnosed. To minimise this problem, the analysis was 
restricted to children born before 2017 and included 
children reported until end of 2018, thus allowing for a 
diagnosis delay of up to 2 years.
The extrapolated numbers of women being diagnosed 
with HIV during pregnancy and those living with diag-
nosed HIV and becoming pregnant, based on the SHI 
subsample from 2011 to 2015 may be underestimated 
because of a biased distribution in different SHIs. 
Figure 4
Estimated HIV screening rates in pregnancy and HIV 
mother-to-child transmission rates, Germany, 2001–2016
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While the number of pregnancies in our SHI subsample 
remained stable across the 5-year observation period, 
population statistics demonstrated an increase in the 
number of pregnancies. This increase is at least partly 
associated with increased immigration [18,25], and 
women who have recently immigrated may be less 
represented in the SHIs constituting our SHI subsam-
ple. In addition, women living with HIV and becoming 
pregnant may not yet be covered by SHI but by publicly 
funded healthcare for asylum seekers, particularly in 
the years 2014 to 2016. Other groups not covered by 
SHI in Germany and thus lacking access to healthcare 
are undocumented migrants and EU citizens without 
valid health insurance.
Conclusions
The expansion of HIV screening in pregnancy in com-
bination with highly effective medical interventions 
to prevent HIV MTCT has successfully minimised HIV 
infections among newborns. To achieve further pro-
gress towards elimination of MTCT of HIV in Germany, 
all pregnant women need to be offered HIV screening 
and healthcare access barriers for migrant women and 
asylum seekers need to be reduced.
This analysis is contingent upon the particularities of 
the German healthcare system. While improved HIV 
screening of pregnant women and general trends such 
as the shift in HIV transmissions from drug use-asso-
ciated risks to sexually acquired infections in women 
may be generalisable to other EU countries, efforts to 
eliminate HIV MTCT in other healthcare systems may 
differ. Compiling an overview of HIV MTCT elimination 
efforts across all EU countries was beyond the scope 
of this analysis, but it would be desirable to have such 
an overview at the European level.
Acknowledgements
This analysis is based on data received from KBV (pregnancy 
HIV screening reimbursement data); data from a SHI sub-
sample prepared and analysed by Josephine Jacob, Institut 
für angewandte Gesundheitsforschung Berlin GmbH; data 
from a mathematical modified back-calculation model of the 
German HIV epidemic prepared by Matthias an der Heiden, 
Robert Koch Institute, Berlin; data from a special study 
conducted from 1993 through 1998 on behalf of the AIDS 
Centre at the Federal Health Agency (BGA) to determine 
HIV prevalence in left-over samples of anonymous unlinked 
dried blood spots collected in the federal states of Berlin 
and Lower Saxony to determine PKU levels in newborn sam-
ples; and pregnancy and childbirth data from the Federal 
Statistical Office of the Federal Republic of Germany.
The author would like to acknowledge Matthias an der 
Heiden and Viviane Bremer for their support and critical ad-
vice on the manuscript.
The author would like to thank all clinicians, paediatricians, 
gynaecologists and HIV care providers who provide care to 
HIV-infected pregnant women, as well as HIV-exposed and 
HIV-infected children in Germany, and who contributed to 
this analysis by reporting infections and providing additional 
information on mother-to-child transmissions of HIV.
Funding: No specific funding was received for this 
manuscript.
Conflict of interest
None declared.
Authors’ contributions
The manuscript and the analyses were conceived by UM. UM 
wrote the drafts and finalised the manuscript.
References
1. World Health Organization Regional Office for Europe (WHO/
Europe). Action plan for the health sector response to HIV in 
the WHO European Region. Copenhagen: WHO/Europe; 2016. 
Available from: http://www.euro.who.int/__data/assets/pdf_
file/0010/315649/66wd09e_HIVActionPlan_160560.pdf
2. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, 
Lauper U, et al. Prevention of vertical HIV transmission: 
additive protective effect of elective Cesarean section and 
zidovudine prophylaxis. AIDS. 1998;12(2):205-10.  https://doi.
org/10.1097/00002030-199802000-00011  PMID: 9468370 
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, 
O’Sullivan MJ, et al. Reduction of maternal-infant transmission 
of human immunodeficiency virus type 1 with zidovudine 
treatment. Pediatric AIDS Clinical Trials Group Protocol 076 
Study Group. N Engl J Med. 1994;331(18):1173-80.  https://doi.
org/10.1056/NEJM199411033311801  PMID: 7935654 
4. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. 
Antiretrovirals for reducing the risk of mother-to-child 
transmission of HIV infection. Cochrane Database Syst Rev. 
2011; (7):CD003510.  https://doi.org/10.1002/14651858.
CD003510.pub3  PMID: 21735394 
5. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, 
Wang L, et al. Abbreviated regimens of zidovudine prophylaxis 
and perinatal transmission of the human immunodeficiency 
virus. N Engl J Med. 1998;339(20):1409-14.  https://doi.
org/10.1056/NEJM199811123392001  PMID: 9811915 
6. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, 
Mwatha A, et al. Effect of breastfeeding and formula feeding 
on transmission of HIV-1: a randomized clinical trial. JAMA. 
2000;283(9):1167-74.  https://doi.org/10.1001/jama.283.9.1167  
PMID: 10703779 
7. Kennedy CE, Yeh PT, Pandey S, Betran AP, Narasimhan 
M. Elective cesarean section for women living with HIV: a 
systematic review of risks and benefits. AIDS. 2017;31(11):1579-
91.  https://doi.org/10.1097/QAD.0000000000001535  PMID: 
28481770 
8. de Vincenzi IKesho Bora Study Group. Triple antiretroviral 
compared with zidovudine and single-dose nevirapine 
prophylaxis during pregnancy and breastfeeding for prevention 
of mother-to-child transmission of HIV-1 (Kesho Bora study): a 
randomised controlled trial. Lancet Infect Dis. 2011;11(3):171-
80.  https://doi.org/10.1016/S1473-3099(10)70288-7  PMID: 
21237718 
9. Federal Joint Committee (G-BA). Mutterschafts-Richtlinien. 
Richtlinien über die ärztliche Betreuung während der 
Schwangerschaft und nach der Entbindung. [Maternity 
Guidelines. Guidelines for antenatal and postnatal care]. 
Berlin: G-BA. [Accessed 13 Nov 2019]. German. Available from: 
https://www.g-ba.de/informationen/richtlinien/19/#tab/
historie/list/%2Finformationen%2Frichtlinien%2Fhistorie%2Fz
ur-richtlinie%2F19%2Fmit%2F10%2Fals%2FGbaWebsiteBundle
%3ARichtlinieVersion%3AajaxList.html.twig%2F
10. German AIDS Society (DAIG)/Austrian AIDS Society. 
Deutsch-Österreichische Leitlinie zur HIV-Therapie in der 
Schwangerschaft und bei HIV-exponierten Neugeborenen. 
[German-Austrian guidelines for HIV treatment during 
pregnancy and for HIV-exposed neonates]. DAIG; March 2017. 
German. Available from: http://www.awmf.org/uploads/
tx_szleitlinien/055-002l_S2k_HIV-Therapie_Schwangerschaft_
Neugeborenen_2017-07.pdf
11. Federal Office of Statistics. Population, Births. Wiesbaden: 
Federal Office of Statistics. [Accessed 20 Jan 2019]. Available 
from: https://www.destatis.de/EN/FactsFigures/SocietyState/
Population/Births/Births.html;jsessionid=EEEA0D1EBD99EBB4
24C58F719B15592A.InternetLive2
10 www.eurosurveillance.org
12. Robert Koch Institute. HIV Screening bei Neugeborenen in 
Deutschland. [HIV screening among neonates in Germany]. 
Epidemiologisches Bulletin. 25 Jul 1997;30:199-200. 
German. Available from: https://www.rki.de/DE/Content/
Infekt/EpidBull/Archiv/1997/Ausgabenlinks/30_97.
pdf?__blob=publicationFile
13. Niehaus F. Geburten- und Kinderzahl im PKV-GKV-Vergleich. 
Eine Analyse der Entwicklung von 2000 bis 2010. [Comparing 
private and statutory health insurances in Germany regarding 
number of births and number of children, 2000-2010]. Cologne: 
Wissenschaftliches Institut der Privaten Krankenversicherung 
(WIP); 2012. German. Available from: http://www.wip-pkv.
de/forschungsbereiche/detail/geburten-und-kinderzahl-im-
pkv-gkv-vergleich-eine-analyse-der-entwicklung-von-2000-
bis-2010.html
14. Robert Koch Institute. Schätzung der Zahl der HIV-
Neuinfektionen und der Gesamtzahl von Menschen mit HIV 
in Deutschland: Stand Ende 2016. [Estimating incident HIV 
infections and prevalence of people living with HIV in Germany 
as of end of 2016]. Epidemiologisches Bulletin. 23 Nov 
2017;47:531-544. German. Available from: https://www.rki.
de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/47_17.
pdf?__blob=publicationFile
15. Cliffe S, Cortina-Borja M, Nicoll A, Newell ML. Interpreting 
neonatal HIV seroprevalence data in Great Britain: the 
importance of differential fertility. Commun Dis Public Health. 
2004;7(1):30-5. PMID: 15137278 
16. Cornford CS, Close HJ, Bray R, Beere D, Mason JM. 
Contraceptive use and pregnancy outcomes among opioid 
drug-using women: a retrospective cohort study. PLoS 
One. 2015;10(3):e0116231.  https://doi.org/10.1371/journal.
pone.0116231  PMID: 25739018 
17. United Nations Department of Economic and Social Affairs 
(DESA) Population Division. World Population Prospects, Maps, 
Total Fertility Rate. New York: DESA. [Accessed 13 Nov 2019]. 
Available from: https://esa.un.org/unpd/wpp/Maps/
18. Bundesinstitut für Bevölkerungsforschung (BiB). 
Migration. Zusammengefasste Geburtenziffer deutscher 
und ausländischer Frauen in Deutschland, 2000 bis 2016. 
[Migration. Total fertility rates of women of German and foreign 
origin in Germany, 2000 to 2016]. Wiesbaden: BiB. [Accessed 
13 Nov 2019]. German. Available from: https://www.bib.bund.
de/DE/Fakten/Fakt/B43-Zusammengefasste-Geburtenziffer-
Nationalitaet-ab-2000.html?nn=9992204
19. Bundesamt für Migration und Flüchtlinge (BAMF). Das 
Bundesamt in Zahlen 2017: Asyl Migration und Integration. 
[The Federal Agency for Migration and Refugees in numbers 
2017: Asylum, migration and integration]. Nuremberg: 
BAMF. [Accessed 14 Nov 2019]. German. Available 
from: https://www.bamf.de/SharedDocs/Anlagen/DE/
Statistik/BundesamtinZahlen/bundesamt-in-zahlen-2017.
pdf?__blob=publicationFile&v=14
20. UNAIDS. Communities at the Centre: Global AIDS Update 
2019. Geneva: UNAIDS; 2019. [Accessed 14 Nov 2019]. 
Available from: https://www.unaids.org/sites/default/files/
media_asset/2019-global-AIDS-update_en.pdf
21. European Collaborative Study. The mother-to-child HIV 
transmission epidemic in Europe: evolving in the East and 
established in the West. AIDS. 2006;20(10):1419-27.  https://
doi.org/10.1097/01.aids.0000233576.33973.b3  PMID: 16791017 
22. Sedgh G, Singh S, Hussain R. Intended and unintended 
pregnancies worldwide in 2012 and recent trends. Stud Fam 
Plann. 2014;45(3):301-14.  https://doi.org/10.1111/j.1728-
4465.2014.00393.x  PMID: 25207494 
23. Chen W-J, Walker N. Fertility of HIV-infected women: 
insights from Demographic and Health Surveys. Sex Transm 
Infect. 2010;86(Suppl 2):ii22-7.  https://doi.org/10.1136/
sti.2010.043620  PMID: 21106511 
24. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) 
for treating HIV infection in ART-eligible pregnant women. 
Cochrane Database Syst Rev. 2010; (3):CD008440.  https://doi.
org/10.1002/14651858.CD008440  PMID: 20238370 
25. Bundesinstitut für Bevölkerungsforschung (BiB). Migration. 
Ausländische Bevölkerung in Deutschland, 1970-2016. 
[Migration. Foreign population in Germany, 1970 to 2016]. 
Wiesbaden: BiB. [Accessed 14 Nov 2019]. German. Available 
from: https://www.bib.bund.de/DE/Fakten/Fakt/B39-
Auslaendische-Bevoelkerung-ab-1970.html?nn=9992204
License, supplementary material and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate
credit to the source, provide a link to the licence and indicate 
if changes were made. 
Any supplementary material referenced in the article can be 
found in the online version.
This article is copyright of the authors or their affiliated in-
stitutions, 2019.
